title: Seroepidemiology of Helicobacter pylori infection in heart transplant recipients.
abstract: We analyzed serum samples obtained from 100 heart transplant recipients before and after transplantation for the presence of IgG antibodies to Helicobacter pylori. Enzyme-linked immunosorbent assay revealed that 35 patients were seropositive before the procedure. Seropositive patients were older than seronegative patients, but the two groups did not differ in terms of cardiac diagnosis, gender, survival, or the number of admissions or rejection episodes. In addition, seropositive patients did not have more-frequent episodes of gastritis, ulcer disease, or gastrointestinal bleeding. Over a mean serological follow-up of 3.4 years, only one of 65 seronegative patients seroconverted. Of the 35 seropositive patients, 14 became seronegative for H. pylori a median of 194 days (range, 47-2,657 days) after transplantation. Seroreverters, as compared with serofast patients, had received more intravenous and total antibiotics during follow-up (P = .01), were more likely to have received a combination of antibiotics active against H. pylori (P < .025), and had received more antirejection treatment (P = .01). The incidence of H. pylori infection is not increased after heart transplantation, and many seropositive patients serorevert after transplantation when antibacterial and immunosuppressive agents are administered.
authors.affiliation: Department of Cardiovascular Surgery, School of Medicine, University of Pittsburgh, Pennsylvania, USA.
authors.forename: J S
authors.initials: JS
authors.lastname: Dummer
authors.forename: G I
authors.initials: GI
authors.lastname: Perez-Perez
authors.forename: M K
authors.initials: MK
authors.lastname: Breinig
authors.forename: A
authors.initials: A
authors.lastname: Lee
authors.forename: S N
authors.initials: SN
authors.lastname: Wolff
authors.forename: R
authors.initials: R
authors.lastname: Kormos
authors.forename: B P
authors.initials: BP
authors.lastname: Griffith
authors.forename: M J
authors.initials: MJ
authors.lastname: Blaser
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000907:Antibodies, Bacterial / Q000097:blood; D005260:Female; D016027:Heart Transplantation / Q000009:adverse effects* / Q000276:immunology; D016481:Helicobacter Infections / Q000453:epidemiology / Q000209:etiology* / Q000382:microbiology; D016480:Helicobacter pylori / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D016036:Seroepidemiologic Studies; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents